TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02212457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
Study: NCT03190369

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Intra articular
Study: NCT04840173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: During attendance at a one hour, 6-week psychosocial classroom or virtual training, caregivers will learn to use singing and other music-based interventions, implementing them each week before the informational session.
Study: NCT03517124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceramic tooth restoration
Description: Dental restorations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic tooth restoration
Description: Dental restorations
Study: NCT01387399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
Description: Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)
Study: NCT02028338

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dapivirine ring
Description: intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
Study: NCT03912571

Intervention type: DIAGNOSTIC_TEST
Intervention: Structural 3T MRI
Description: measures of global and hippocampal atrophy)
Study: NCT01348607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02197793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization Program
Study: NCT00567593

Intervention type: DRUG
Group type: OTHER
Intervention: Rosiglitazone
Description: 8mg tablet once a day for 14 days
Study: NCT02476422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Single dose of diclofenac 50 mg soft gelatin capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Single dose of ibuprofen 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ibuprofen
Description: Single dose of placebo to ibuprofen 400 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to diclofenac potassium
Description: Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
Study: NCT02743663

Intervention type: DRUG
Intervention: salbutamol
Description: Given during bronchodilator response.

Intervention type: PROCEDURE
Intervention: Nasal Brush
Description: Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).

Intervention type: PROCEDURE
Intervention: Blood sample
Description: 8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.

Intervention type: PROCEDURE
Intervention: Basophil activation test
Description: Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.

Intervention type: PROCEDURE
Intervention: Nasal swab
Description: Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
Study: NCT03671993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45\~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical instillation
Description: The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
Study: NCT01859143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: A single dose of 10\^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study: NCT05702866

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcutaneous oximetry
Description: Comparison of the TcpO2 values recorded during dynamic maneuver with the estimated rate of compression of the subclavian and axillary vessels determined on dynamic angiography.
Study: NCT00689598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg po qd 25 mg po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone
Description: 25 mg po qd 25 mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Spironolactone 25 mg po qd
Study: NCT02212457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
Study: NCT04440696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Polystyrene Sulphonate Powder
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Polystyrene Sulphonate Powder
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Polystyrene Sulphonate Powder
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Polystyrene Sulphonate Powder
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate 500 MG
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate 500 MG
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate 500 MG
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate 500 MG
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Study: NCT03414034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone orally
Study: NCT04629170

Intervention type: DRUG
Group type: OTHER
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
Study: NCT02275754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PN+LCNC
Description: Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PN Only
Description: Participants will be navigated by PN on request
Study: NCT01591915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
Study: NCT00743860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: experimental drug
Study: NCT02141048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Parenting Skills Training
Description: This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
Study: NCT03930849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIMS
Description: Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIMS plus
Description: Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
Study: NCT00239824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training of the pelvic floor muscles
Description: Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist
Study: NCT02398734

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sonolysis
Description: Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonolysis
Description: Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
Study: NCT00258856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01713166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plasmalyte solution
Description: plasmalyte solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hextend
Description: Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
Study: NCT03692169

Intervention type: PROCEDURE
Intervention: Half-dose photodynamic therapy
Description: Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
Study: NCT00859885

Intervention type: DRUG
Intervention: Antithrombotic treatment
Description: antiplatelets, anticoagulants

Intervention type: DEVICE
Intervention: percutaneous device closure of PFO
Description: umbrella device for PFO closure
Study: NCT04463927

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-nutritive sucking
Description: intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
Study: NCT04545892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
Study: NCT04114825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV001V
Description: RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
Study: NCT03218475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Guided Focused Ultrasound
Description: Two treatments of focused ultrasound under MRI guidance
Study: NCT01589328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative care integrated with usual oncologic care
Description: Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education